Axel Grothey

Axel Grothey contributed to the IDEA North American consortium and has been a leading advocate for risk-stratified adjuvant duration in stage III colon cancer based on IDEA trial results. His research on minimizing cumulative neuropathy while maintaining oncological outcomes has influenced widespread adoption of 3-month CAPOX in low-risk stage III colon cancer. He has contributed to multiple practice-changing publications on adjuvant and metastatic CRC therapy. Grothey is widely recognized for translating complex clinical trial data into practical treatment algorithms for colorectal oncology.